Although over the last decade, many studies have shown that noninvasive methods, such as ultrasound, transient elastography, and simple blood tests, can accurately predict the presence of clinically significant portal hypertension (CSPH), most were performed in viral hepatitis-related cirrhosis patients [1] [2] [3] [4] [5] [6] [7] . Until very recently, the European Association for the Study of the Liver (EASL) guidelines stated that there was not enough evidence to replace endoscopy with noninvasive methods [8] . Baveno [14] . Augustin et al. [15] compiled publications and abstracts regarding the validation of the Baveno VI report (a total of 3 publications and 6 abstracts) with a total of 2,500 patients, applying the criteria to 1,000. The guidelines could have spared 20% of endoscopies, but still missed patients who needed primary prophylaxis and, in almost 40% of the patients, an endoscopy could have been avoided altogether [15] .
The Baveno consensus report was a first step in the direction of applying noninvasive methods to select patients for endoscopy screening. Further research developing new cutoffs or applying other noninvasive methods is needed. In this issue, in "Baveno VI Recommendation on Avoidance of Endoscopy in Cirrhotic Patients: Are We There Yet?" Silva et al. [16] set out to determine the Baveno VI criteria in a retrospective cohort of 97 patients with hepatitis C-associated cirrhosis. In this cohort, endoscopy was avoided in 11.3% of patients, and it further suggested that by skewing the cutoffs to <120,000 platelets and liver stiffness to >30 kPa, endoscopy could be avoided in 27.8% of patients, supporting the validation of the Baveno VI recommendations [16] .
There is still a clear lack of prospective data validating the Baveno VI recommendations in patients with cACLD with different etiologies (nonviral causes, such as alcoholic and nonalcoholic liver disease, are underrepresented in most studies) and establishing that endoscopy avoidance is clearly safe and cost-effective. Although a large proportion of patients can avoid endoscopic screening, it is important to underline that some patients are misclassified and will not be offered primary prophylaxis.
A step in the right direction was taken in the recently published ANTICIPATE study, a multinational study including 518 cACLD patients that blended retrospective and prospective data. The aim of this study was to develop continuous risk prediction models based on noninvasive methods to predict the risk of CSPH, varices, and varices needing treatment in a large multinational cohort of compensated cirrhotic patients who had paired noninvasive tests (transient elastography, spleen diameter, and platelet count) and endoscopy or hepatic venous pressure gradient measurement. The study successfully developed nomograms that could predict the development of CSPH and varices requiring treatment in patients with compensated cirrhosis. The same simple noninvasive tools could not reliably identify the population of patients having a low risk of all-size varices, partly explained by the fact that endoscopy is not a perfect gold standard for the diagnosis of gastroesophageal varices [17] . Although this study developed an accurate predictive model based on a large number of patients from various centers, prospective studies including more cirrhotic patients with nonviral etiologies are needed to further validate the findings.
The response to the question "Baveno VI recommendation on avoidance of screening endoscopy in cirrhotic patients -are we there yet?" is: not quite and look before you leap!
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